SCHEMBL9890784

SCHEMBL9890784

CC(C)(C)NC(=O)Cc1ccccc1-c1ccccc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANO1 Q5XXA6 5/20 0.47
RAB9A P51151 4/20 0.46
LMNA P02545 3/20 0.46
RIPK1 Q13546 1/20 0.44
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 1/20 0.43
TSHR P16473 1/20 0.43
PPIA P62937 1/20 0.43
ALDH1A1 P00352 2/20 0.42
ADORA2A P29274 2/20 0.42
ADORA1 P30542 2/20 0.42
ADORA3 P0DMS8 1/20 0.42
ADORA2B P29275 1/20 0.42
NPC1 O15118 3/20 0.41
GAA P10253 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2395314 0.83 RAB9A (0.49) RAB9ALMNARIPK1MAPTHPGD
SCHEMBL9890723 0.80 LMNA (0.47) RAB9ALMNARIPK1HPGDPPIA
SCHEMBL25144070 0.79 ANO1 (0.61) ANO1LMNARIPK1HPGDALDH1A1
SCHEMBL14019877 0.77 PPIA (0.57) ANO1RAB9ALMNARIPK1TSHR
SCHEMBL9890798 0.76 SIGMAR1 (0.55) LMNAHPGDTSHRPPIAALDH1A1
SCHEMBL538984 0.75 CXCL8 (0.57) RAB9ALMNAALDH1A1MEN1KMT2A
SCHEMBL10989847 0.74 ANO1 (0.57) ANO1RAB9ALMNAMAPTHPGD
SCHEMBL2391854 0.74 ALDH1A1 (0.45) RAB9ALMNAMAPTPPIAALDH1A1
SCHEMBL13607973 0.74 ANO1 (0.51) ANO1RAB9ALMNARIPK1HPGD
SCHEMBL2393306 0.73 ALDH1A1 (0.42) RAB9ALMNARIPK1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 ANO1 3004/4885RAB9A 208/4885LMNA 3980/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 ANO1 3004/4885RAB9A 208/4885LMNA 3980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.